These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16254790)

  • 41. CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis.
    Simelyte E; Criado G; Essex D; Uger RA; Feldmann M; Williams RO
    Arthritis Rheum; 2008 Apr; 58(4):1038-43. PubMed ID: 18383359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. T-cell-activation inhibitors in rheumatoid arthritis.
    Lorenz HM
    BioDrugs; 2003; 17(4):263-70. PubMed ID: 12899643
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis.
    Cutolo M; Nadler SG
    Autoimmun Rev; 2013 May; 12(7):758-67. PubMed ID: 23340277
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MicroRNA-766-3p Contributes to Anti-Inflammatory Responses through the Indirect Inhibition of NF-κB Signaling.
    Hayakawa K; Kawasaki M; Hirai T; Yoshida Y; Tsushima H; Fujishiro M; Ikeda K; Morimoto S; Takamori K; Sekigawa I
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30769772
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis.
    Bonelli M; Göschl L; Blüml S; Karonitsch T; Hirahara K; Ferner E; Steiner CW; Steiner G; Smolen JS; Scheinecker C
    Rheumatology (Oxford); 2016 Apr; 55(4):710-20. PubMed ID: 26672908
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.
    Reynolds J; Shojania K; Marra CA
    Pharmacotherapy; 2007 Dec; 27(12):1693-701. PubMed ID: 18041889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide.
    Luo Q; Sun Y; Liu W; Qian C; Jin B; Tao F; Gu Y; Wu X; Shen Y; Xu Q
    J Immunol; 2013 Nov; 191(10):4969-78. PubMed ID: 24123677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Interleukin-1 in pathogenesis of rheumatoid arthritis].
    Iwakura Y
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():153-7. PubMed ID: 15799336
    [No Abstract]   [Full Text] [Related]  

  • 49. CD200/CD200R paired potent inhibitory molecules regulating immune and inflammatory responses; Part I: CD200/CD200R structure, activation, and function.
    Holmannová D; Kolácková M; Kondélková K; Kunes P; Krejsek J; Andrýs C
    Acta Medica (Hradec Kralove); 2012; 55(1):12-7. PubMed ID: 22696929
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deal watch: Bristol-Myers Squibb acquires potential keys to treating rheumatoid arthritis.
    Cully M
    Nat Rev Drug Discov; 2016 May; 15(5):301. PubMed ID: 27139990
    [No Abstract]   [Full Text] [Related]  

  • 51. Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling.
    Choe JY; Crain B; Wu SR; Corr M
    J Exp Med; 2003 Feb; 197(4):537-42. PubMed ID: 12591910
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emerging therapeutics for rheumatoid arthritis.
    Bingham CO
    Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-arthritic agents: progress and potential.
    Laev SS; Salakhutdinov NF
    Bioorg Med Chem; 2015 Jul; 23(13):3059-80. PubMed ID: 26014481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Accelerated Progression of Hepatocellular Carcinoma during Immunosuppressive Therapy with Abatacept for Rheumatoid Arthritis.
    Yoshiji S; Takahashi K; Sawada K; Mishima M; Eso Y; Morita M; Takai A; Marusawa H; Ueda Y; Mimori T; Seno H
    Intern Med; 2019 Jan; 58(1):67-71. PubMed ID: 30146566
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abatacept for Treatment of Rheumatoid Arthritis: Special Focus on the Elderly.
    Soubrier M; Lahaye C; Tatar Z
    Drugs Aging; 2018 May; 35(5):379-387. PubMed ID: 29651639
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Leonurine attenuates fibroblast-like synoviocyte-mediated synovial inflammation and joint destruction in rheumatoid arthritis.
    Li N; Xu Q; Liu Q; Pan D; Jiang Y; Liu M; Liu M; Xu H; Lin C
    Rheumatology (Oxford); 2017 Aug; 56(8):1417-1427. PubMed ID: 28431044
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mycoplasma arthritidis superantigen (MAM)-induced macrophage nitric oxide release is MHC class II restricted, interferongamma dependent, and toll-like receptor 4 independent.
    Ribeiro-Dias F; Shio MT; Timenetsky J; Oliane AP; Metran CC; Pessoa FB; Jancar S
    Exp Cell Res; 2003 Jun; 286(2):345-54. PubMed ID: 12749862
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis].
    Sibilia J
    Med Sci (Paris); 2009 Dec; 25(12):1033-8. PubMed ID: 20035675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Investigational agents for rheumatoid arthritis.
    Merkel PA; Letourneau EN; Polisson RP
    Rheum Dis Clin North Am; 1995 Aug; 21(3):779-96. PubMed ID: 8619099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.